Adjuvant Colon Cancer w/ ELOXatin®/5 FU Based Regimen: ACCELOX

Adjuvant Colon Cancer With ELOXatin®/5 FU Based Regimen: ACCELOX

Completed

Looking for future studies?

Key information

Conditions

Colon Cancer Colonic Diseases Colonic Neoplasms Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms Neoplasms Neoplasms by Site

Age range

14 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Kfsh & Rc

Riyadh, Saudi Arabia

About this study

It's a study of adjuvant colon carcinoma using ELOXatin/5-FU based chemotherapeutic regimen called ACCELOX as a definitive curative therapy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with Adjuvant Colon Cancer

Exclusion criteria

Patients with diagnosis other than Colon Cancer.

Treatment and study plan

Registry

Other

Registry

Primary outcomes

OS, PFS, DFS

Time frame: For the duration of the experiment

Sponsors and collaborators

Lead sponsor

King Faisal Specialist Hospital & Research Center

Other

Registry information

Official study title

Adjuvant Colon Cancer With ELOXatin®/5 FU Based Regimen: ACCELOX

Important dates

Study start: 2007
Primary completion: 2007
Study completion: 2007
First posted: Mar 9, 2011
Registry last updated: Aug 10, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed